biostudies-literatureKokabi NRadiological Society of North AmericaNCI NIH HHSSirtex Medical Ltd1743-1752https://www.ebi.ac.uk/biostudies/studies/S-EPMC10119065biostudies-literatureUnknown50(6)<h4>Background</h4>There is an increasing body of evidence indicating Y90 dose thresholds for tumor response and treatment-related toxicity. These thresholds are poorly studied in resin Y90, particularly in hepatocellular carcinoma (HCC).<h4>Purpose</h4>To evaluate the efficacy of prospective voxel-based dosimetry for predicting treatment response and adverse events (AEs) in patients with HCC undergoing resin-based Y90 radioembolization.<h4>Materials and methods</h4>This correlative study was based on a prospective single-arm clinical trial (NCT04172714), which evaluated the efficacy of low/scout (555 MBq) activity of resin-based Y90 for treatment planning. Partition model was used with goal of tumor dose (TD) > 200 Gy and non-tumoral liver dose (NTLD) < 70 Gy for non-segmental therapies. European journal of nuclear medicine and molecular imagingVoxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.PMC10119065P30 CA008748Investigator Initiated StudyResearch Scholar GrantArndt-Webster LBercu ZDavarpanahfakhr AKokabi NKappadath SCBrandon DSchuster DMElsayed MChen BGalt JSethi ICristescu MfalseVoxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.<h4>Background</h4>There is an increasing body of evidence indicating Y90 dose thresholds for tumor response and treatment-related toxicity. These thresholds are poorly studied in resin Y90, particularly in hepatocellular carcinoma (HCC).<h4>Purpose</h4>To evaluate the efficacy of prospective voxel-based dosimetry for predicting treatment response and adverse events (AEs) in patients with HCC undergoing resin-based Y90 radioembolization.<h4>Materials and methods</h4>This correlative study was based on a prospective single-arm clinical trial (NCT04172714), which evaluated the efficacy of low/scout (555 MBq) activity of resin-based Y90 for treatment planning. Partition model was used with goal of tumor dose (TD) > 200 Gy and non-tumoral liver dose (NTLD) < 70 Gy for non-segmental therapies. 2023-01-01T00:00:00Z2023 May2025-04-04T10:22:26.407Z2025-02-19T02:38:19.472ZS-EPMC101190653665035710.1007/s00259-023-06111-9